BERNAMA – Unit 731 Site To Become Cultural Park

See on Scoop.itBiodefense News

HARBIN, Feb 28 (Bernama) — National approval has been granted to turn the site of Japan’s notorious Unit 731 in northeast China’s Harbin into a cultural park, Xinhua news agency reported.

The park will be built upon the ruins of Unit 731 and will exhibit artifacts of biological and chemical warfare, said a source with the Exhibition Hall of Crime Evidence of Japanese Germ Factory in Heilongjiang province’s capital Harbin.


See on www.bernama.com

Menon Biosensors M2 Technology Demonstrates Wide Dynamic Range for Pathogen Detection and… — SAN DIEGO, Feb. 28, 2014 /PRNewswire/ –

See on Scoop.itBiodefense News

SAN DIEGO, Feb. 28, 2014 /PRNewswire/ — Menon Biosensors M2 Technology Demonstrates Wide Dynamic Range for Pathogen Detection and Quantification. M2 technology expands applications through massive increase in quantification with sample to answer in less than one hour.


See on www.prnewswire.com

Viruses in UAE to be tracked by satellite to prevent outbreaks – Zawya (registration)

See on Scoop.itBiodefense News

Viruses in UAE to be tracked by satellite to prevent outbreaks Zawya (registration) “The increase in prevalence of many infectious diseases together with the on-going evolution of viral and microbial variants, and selection for drug resistance,…


Biodefense News‘s insight:

Interesting proposition.


See on news.google.com

DTRA: Novel Mechanism Based Multiple Drug Resistance Broad Spectrum Anti-Threat Bacterial Pathogens Antibiotics – Federal Business Opportunities: Opportunities

See on Scoop.itBiodefense News

The objective of this RFI is to identify candidate Small organic Molecules Inhibitors (SMI) that have the potential to potently and specifically inhibit multiple drug resistance (MDR) bacterial pathogens including tier-1 CDC/DoD listed bacteria.

The DoD is interested in exploring availability of SMIs that possess new mechanism of action(s) and are bactericidal against broad MDR bacterial infectious pathogens. DoD welcomes engagement of all sources that have reached at an advanced Phase I clinical studies or completed this clinical Phase.


See on www.fbo.gov